Evaluation/NN
and/CC
Interpretation/NN
of/IN
Transcriptome/JJ
Data/NNS
Underlying/VBG
Heterogeneous/JJ
Chronic/JJ
Obstructive/JJ
Pulmonary/JJ
Disease/NN
./.
====================
Chronic/JJ
obstructive/JJ
pulmonary/JJ
disease/NN
(/(
COPD/NN
)/)
is/VBZ
a/DT
type/NN
of/IN
progressive/JJ
lung/NN
disease/NN
,/,
featured/JJ
by/IN
airflow/NN
obstruction/NN
./.
====================
Recently/RB
,/,
a/DT
comprehensive/JJ
analysis/NN
of/IN
the/DT
transcriptome/JJ
in/IN
lung/NN
tissue/NN
of/IN
COPD/NN
patients/NNS
was/VBD
performed/VBN
,/,
but/CC
the/DT
heterogeneity/NN
of/IN
the/DT
sample/JJ
was/VBD
not/RB
seriously/RB
considered/VBN
in/IN
characterizing/VBG
the/DT
mechanistic/JJ
dysregulation/NN
of/IN
COPD/NN
./.
====================
Here/RB
,/,
we/PRP
established/VBD
a/DT
new/JJ
transcriptome/JJ
analysis/NN
pipeline/NN
using/VBG
a/DT
deconvolution/NN
process/NN
to/TO
reduce/VB
the/DT
heterogeneity/NN
and/CC
clearly/RB
identified/VBN
that/WDT
these/DT
transcriptome/JJ
data/NNS
originated/VBN
from/IN
the/DT
mild/JJ
or/CC
moderate/JJ
stage/NN
of/IN
COPD/NN
patients/NNS
./.
====================
Differentially/RB
expressed/VBN
or/CC
co-expressed/VBN
genes/NNS
in/IN
the/DT
protein/NN
interaction/NN
subnetworks/NNS
were/VBD
linked/VBN
with/IN
mitochondrial/JJ
dysfunction/NN
and/CC
the/DT
immune/JJ
response/NN
,/,
as/IN
expected/VBN
./.
====================
Computational/JJ
protein/NN
localization/NN
prediction/NN
revealed/VBD
that/IN
19/CD
proteins/NNS
showing/VBG
changes/NNS
in/IN
subcellular/JJ
localization/NN
were/VBD
mostly/RB
related/JJ
to/TO
mitochondria/NN
,/,
suggesting/VBG
that/IN
mislocalization/NN
of/IN
mitochondria-targeting/JJ
proteins/NNS
plays/VBZ
an/DT
important/JJ
role/NN
in/IN
COPD/NN
pathology/NN
./.
====================
Our/PRP$
extensive/JJ
evaluation/NN
of/IN
COPD/NN
transcriptome/VBP
data/NNS
could/MD
provide/VB
guidelines/NNS
for/IN
analyzing/VBG
heterogeneous/JJ
gene/NN
expression/NN
profiles/NNS
and/CC
classifying/VBG
potential/JJ
candidate/NN
genes/NNS
that/WDT
are/VBP
responsible/JJ
for/IN
the/DT
pathogenesis/NN
of/IN
COPD/NN
./.
====================
COPD/NN
,/,
or/CC
chronic/JJ
obstructive/JJ
pulmonary/JJ
disease/NN
,/,
is/VBZ
a/DT
type/NN
of/IN
obstructive/JJ
lung/NN
disease/NN
characterized/VBN
by/IN
long-term/JJ
poor/JJ
airflow/NN
[/(
1/CD
]/)
./.
====================
It/PRP
is/VBZ
a/DT
general/JJ
term/NN
referring/VBG
to/TO
chronic/JJ
bronchitis/NN
,/,
emphysema/FW
,/,
and/CC
refractory/JJ
(/(
non-reversible/JJ
)/)
asthma/NN
./.
====================
These/DT
progressive/JJ
lung/NN
diseases/NNS
are/VBP
commonly/RB
characterized/VBN
by/IN
increased/VBN
shortness/RB
of/IN
breath/NN
,/,
frequent/JJ
coughing/VBG
,/,
increased/VBD
breathlessness/NN
,/,
and/CC
wheezing/VBG
./.
====================
COPD/NN
may/MD
be/VB
caused/VBN
by/IN
a/DT
variety/NN
of/IN
environmental/JJ
factors/NNS
,/,
such/JJ
as/IN
air/NN
pollution/NN
,/,
secondhand/CC
smoke/JJ
,/,
dust/IN
,/,
fumes/VBZ
,/,
and/CC
chemicals/NNS
[/(
2/CD
]/)
./.
====================
It/PRP
is/VBZ
expected/VBN
that/DT
diverse/JJ
causes/VBZ
and/CC
symptoms/NNS
of/IN
COPD/NN
may/MD
lead/VB
to/TO
heterogeneous/JJ
gene/NN
expression/NN
profiles/NNS
in/IN
individual/JJ
COPD/NN
patients/NNS
,/,
as/IN
mentioned/VBN
by/IN
Wedzicha/NN
[/(
3/CD
]/)
./.
====================
Currently/RB
,/,
more/RBR
than/IN
70/CD
%/NN
of/IN
COPD/NN
patients/NNS
suffer/VBP
from/IN
limited/JJ
physical/JJ
activity/NN
,/,
and/CC
50/CD
%/NN
among/IN
them/PRP
can/MD
not/RB
lead/VB
a/DT
normal/JJ
life/NN
[/(
4,5/CD
]/)
./.
====================
In/IN
2015/CD
,/,
COPD/NN
ranked/VBD
as/IN
the/DT
third/JJ
leading/VBG
cause/VBP
of/IN
death/NN
worldwide/NN
,/,
and/CC
it/PRP
is/VBZ
expected/VBN
that/DT
the/DT
mortality/NN
from/IN
COPD/NN
will/MD
increase/VB
greatly/RB
by/IN
2030/CD
[/(
1/CD
]/)
./.
====================
Smoking/JJ
causes/VBZ
about/RB
80/CD
%/NN
to/TO
90/CD
%/NN
of/IN
all/DT
deaths/NNS
from/IN
COPD/NN
[/(
2/CD
]/)
./.
====================
Chemical/JJ
compounds/NNS
in/IN
tobacco/NN
smoke/JJ
may/MD
impair/VB
immunity/NN
to/TO
respiratory/JJ
infections/NNS
and/CC
increase/VBP
the/DT
risk/NN
of/IN
lung/NN
damage/NN
./.
====================
The/DT
number/NN
of/IN
female/JJ
COPD/NN
cases/NNS
is/VBZ
increasing/VBG
due/JJ
to/TO
the/DT
use/NN
of/IN
tobacco/NN
in/IN
some/DT
high-income/JJ
countries/NNS
and/CC
exposure/NN
to/TO
air/NN
pollution/NN
in/IN
low-income/JJ
countries/NNS
[/(
5/CD
]/)
./.
====================
However/RB
,/,
25/CD
%/NN
of/IN
all/DT
COPD/NN
patients/NNS
are/VBP
never-smokers/NNS
or/CC
passive/JJ
smokers/NNS
[/(
5/CD
]/)
./.
====================
Genetic/JJ
factors/NNS
also/RB
contribute/VBP
to/TO
the/DT
development/NN
of/IN
COPD/NN
./.
====================
For/IN
example/NN
,/,
alpha-1/NN
antitrypsin/JJ
,/,
a/DT
serum/NN
serine/NN
protease/NN
inhibitor/NN
,/,
functions/VBZ
to/TO
protect/VB
the/DT
lung/NN
from/IN
neutrophil/NN
elastase/NN
,/,
and/CC
its/PRP$
deficiency/NN
allows/VBZ
chronic/JJ
,/,
uninhibited/JJ
inflammation/NN
in/IN
the/DT
lung/NN
,/,
leading/VBG
to/TO
emphysema/DT
,/,
along/IN
with/IN
chronic/JJ
bronchitis/NN
[/(
6/CD
]/)
./.
====================
The/DT
prevalence/NN
of/IN
COPD/NN
is/VBZ
well/RB
documented/VBN
./.
====================
The/DT
diagnostic/JJ
assessment/NN
of/IN
COPD/NN
,/,
as/IN
proposed/VBN
by/IN
the/DT
Global/JJ
Initiative/JJ
for/IN
Chronic/JJ
Obstructive/JJ
Lung/NN
Disease/NN
(/(
GOLD/NN
)/)
,/,
is/VBZ
based/VBN
on/IN
4/CD
multiple/JJ
factors/NNS
,/,
such/JJ
as/IN
the/DT
patient/NN
’/CD
s/NNS
level/NN
of/IN
symptoms/NNS
,/,
the/DT
extent/NN
of/IN
airflow/JJ
obstruction/NN
,/,
spirometric/JJ
abnormality/NN
,/,
and/CC
the/DT
identification/NN
of/IN
comorbidities/NNS
[/(
1/CD
]/)
./.
====================
About/RB
12/CD
million/NN
adults/NNS
in/IN
the/DT
United/JJ
States/NNS
are/VBP
diagnosed/VBN
with/IN
COPD/NN
,/,
and/CC
1/CD
%/NN
of/IN
them/PRP
lose/VBP
their/PRP$
life/NN
from/IN
it/PRP
every/RB
year/NN
./.
====================
Also/RB
,/,
another/DT
12/CD
million/NN
people/NN
in/IN
the/DT
United/JJ
States/NNS
are/VBP
regarded/VBN
as/IN
having/VBG
undiagnosed/VBN
COPD/NN
[/(
7/CD
]/)
./.
====================
However/RB
,/,
most/JJS
undiagnosed/VBN
people/NN
are/VBP
estimated/VBN
to/TO
be/VB
in/IN
the/DT
mild/JJ
or/CC
moderate/JJ
stage/NN
of/IN
COPD/NN
and/CC
are/VBP
not/RB
likely/JJ
to/TO
be/VB
detected/VBN
./.
====================
Many/JJ
case/NN
studies/NNS
have/VBP
considered/VBN
alternative/JJ
diagnostic/JJ
aspects/NNS
,/,
which/WDT
do/VBP
not/RB
seem/VB
enough/IN
to/TO
cover/VB
the/DT
whole/JJ
spectrum/NN
of/IN
COPD/NN
[/(
2,8/CD
]/)
./.
====================
For/IN
example/NN
,/,
inflammatory/JJ
markers/NNS
in/IN
COPD/NN
from/IN
the/DT
Bergen/NN
COPD/NN
cohort/NN
study/NN
have/VBP
been/VBN
used/VBN
for/IN
the/DT
early/JJ
diagnosis/NN
of/IN
COPD/NN
[/(
9/CD
]/)
./.
====================
Recently/RB
,/,
major/JJ
biological/JJ
and/CC
clinical/JJ
discoveries/NNS
have/VBP
been/VBN
allowed/VBN
by/IN
great/JJ
technical/JJ
advances/NNS
in/IN
next-generation/NN
sequencing/NN
techniques/NNS
./.
====================
Kim/NN
et/FW
al/JJ
./.
====================
[/(
10/CD
]/)
analyzed/VBD
RNA/NN
sequencing/NN
(/(
RNA-seq/NN
)/)
data/NNS
of/IN
98/CD
COPD/NN
lung/NN
tissue/NN
samples/NNS
and/CC
91/CD
normal/JJ
samples/NNS
classified/VBN
by/IN
the/DT
GOLD/NN
definition/NN
./.
====================
In/IN
this/DT
study/NN
,/,
they/PRP
identified/VBD
differentially/RB
expressed/VBN
genes/NNS
(/(
DEGs/NNS
)/)
and/CC
isoforms/NNS
(/(
DEIs/NNS
)/)
between/IN
COPD/NN
and/CC
normal/JJ
tissue/NN
./.
====================
But/CC
,/,
DEGs/NNS
and/CC
DEIs/NNS
could/MD
not/RB
be/VB
used/VBN
for/IN
distinguishing/VBG
COPD/NN
from/IN
normal/JJ
tissue/NN
,/,
probably/RB
due/JJ
to/TO
the/DT
heterogeneity/NN
of/IN
the/DT
COPD/NN
samples/NNS
./.
====================
Here/RB
,/,
we/PRP
established/VBD
a/DT
new/JJ
transcriptome/JJ
analysis/NN
pipeline/NN
to/TO
remove/VB
heterogeneity/NN
and/CC
find/VBP
suitable/JJ
markers/NNS
to/TO
clearly/RB
separate/JJ
COPD/NN
from/IN
normal/JJ
tissue/NN
./.
====================
The/DT
removal/NN
of/IN
heterogeneity/NN
enabled/VBD
us/PRP
to/TO
detect/VB
emergent/JJ
gene/NN
expression/NN
changes/NNS
and/CC
protein/NN
interaction/NN
subnetworks/NNS
that/DT
were/VBD
missed/VBN
in/IN
the/DT
previous/JJ
study/NN
./.
====================
Especially/RB
,/,
the/DT
importance/NN
of/IN
mitochondrial/JJ
proteins/NNS
was/VBD
revitalized/VBN
through/IN
our/PRP$
analysis/NN
regarding/VBG
co-expression/NN
relationships/NNS
and/CC
changes/NNS
in/IN
the/DT
subcellular/JJ
localization/NN
of/IN
proteins/NNS
./.
====================
The/DT
analysis/NN
pipeline/NN
used/VBN
in/IN
this/DT
study/NN
could/MD
be/VB
used/VBN
to/TO
classify/VB
heterogeneous/JJ
gene/NN
expression/NN
profiles/NNS
and/CC
predict/VBP
potential/JJ
candidates/NNS
for/IN
COPD/NN
pathogenesis/NN
./.
====================
Exploratory/JJ
analysis/NN
of/IN
gene/NN
expression/NN
profiles/NNS
====================
Raw/NN
RNA-seq/NN
data/NNS
from/IN
98/CD
male/JJ
COPD/NN
and/CC
91/CD
normal/JJ
samples/NNS
were/VBD
downloaded/VBN
from/IN
the/DT
Gene/NN
Expression/NN
Omnibus/JJ
database/NN
(/(
GSE57148/NN
,/,
https/VBZ
:/:
//www.ncbi.nlm.nih.gov/geo//JJ
)/)
./.
====================
The/DT
reads/VBZ
were/VBD
aligned/VBN
to/TO
the/DT
human/JJ
genome/NN
(/(
hg19/NN
)/)
using/VBG
tophat/JJ
(/(
v2.0.9/CD
)/)
and/CC
bowtie2/NN
(/(
v2.1.0.0/CD
)/)
,/,
along/IN
with—segment-length/IN
50—segment-mismatches/NNS
1/CD
[/(
11,12/CD
]/)
./.
====================
The/DT
expression/NN
levels/NNS
of/IN
individual/JJ
transcripts/NNS
by/IN
fragments/NNS
per/IN
kilobase/NN
of/IN
exon/NN
per/IN
million/NN
fragments/NNS
mapped/VBD
(/(
FPKM/NN
)/)
were/VBD
calculated/VBN
by/IN
Cufflinks/NNS
(/(
v2.21/NN
)/)
[/(
13/CD
]/)
./.
====================
A/DT
total/JJ
of/IN
1,420/CD
DEGs/NNS
previously/RB
identified/VBN
by/IN
Kim/NN
et/FW
al/JJ
./.
====================
[/(
10/CD
]/)
were/VBD
used/VBN
for/IN
comparison/NN
purposes/NNS
./.
====================
Principal/JJ
component/NN
analysis/NN
(/(
PCA/NN
)/)
was/VBD
performed/VBN
with/IN
DEGs/NNS
,/,
and/CC
a/DT
three-dimensional/JJ
plot/NN
was/VBD
drawn/VBN
in/IN
R./NNP
p-values/NNS
in/IN
the/DT
bar/JJ
graph/NN
were/VBD
estimated/VBN
by/IN
student/JJ
’/CD
s/NNS
t/NN
test/NN
./.
====================
After/IN
500/CD
repeats/NNS
with/IN
the/DT
e1071/NN
library/NN
in/IN
R/NN
,/,
the/DT
classification/NN
power/JJR
of/IN
certain/JJ
genes/NNS
was/VBD
examined/VBN
by/IN
building/VBG
a/DT
naive/JJ
Bayes/NNS
model/NN
with/IN
10-times/NNS
cross-validation/NN
./.
====================
The/DT
performance/NN
of/IN
individual/JJ
classification/NN
models/NNS
,/,
estimating/VBG
sensitivity/NN
and/CC
specificity/NN
,/,
was/VBD
measured/VBN
by/IN
computing/VBG
area/NN
under/IN
the/DT
curve/JJ
(/(
AUC/NN
)/)
values/NNS
with/IN
the/DT
Receiver/NN
Operating/JJ
characteristic/JJ
Curve/NN
in/IN
R/NN
(/(
ROCR/NN
)/)
package/NN
./.
====================
Measurement/JJ
of/IN
VJ/NN
recombination/NN
events/NNS
====================
Unmapped/JJ
reads/VBZ
were/VBD
collapsed/VBN
,/,
such/JJ
that/IN
repeatedly/RB
appearing/VBG
reads/VBZ
were/VBD
regarded/VBN
as/IN
a/DT
single/JJ
read/VBN
./.
====================
The/DT
read/JJ
count/NN
of/IN
each/DT
sequence/NN
was/VBD
sorted/VBN
in/IN
descending/VBG
order/NN
,/,
and/CC
the/DT
top/NN
10,000/CD
reads/VBZ
were/VBD
selected/VBN
from/IN
individual/JJ
samples/NNS
./.
====================
The/DT
reads/VBZ
corresponding/VBG
to/TO
V/JJ
,/,
D/NN
,/,
J/NNP
regions/NNS
of/IN
the/DT
B/NN
cell/NN
receptor/NN
(/(
BCR/NN
)/)
and/CC
T/NN
cell/NN
receptor/NN
(/(
TCR/NN
)/)
loci/NNS
were/VBD
selected/VBN
by/IN
an/DT
immunoglobulin/NN
variable/JJ
domain/NN
sequence/NN
analysis/NN
tool/NN
,/,
called/VBN
IgBlast/JJ
(/(
http/NN
:/:
//www.ncbi.nlm.nih.gov/igblast//JJ
)/)
[/(
14/CD
]/)
./.
====================
Then/RB
,/,
VJ/NNP
recombination/NN
events/NNS
were/VBD
considered/VBN
,/,
using/VBG
only/RB
in-frame/RB
sequence/NN
reads/VBZ
of/IN
6/CD
V/JJ
,/,
D/NN
,/,
J/NN
regions/NNS
./.
====================
Alpha/NN
and/CC
beta/NN
diversity/NN
levels/NNS
were/VBD
calculated/VBN
by/IN
vegan/JJ
and/CC
the/DT
betapart/NN
library/NN
in/IN
R/NN
,/,
respectively/RB
./.
====================
A/DT
dot/JJ
plot/NN
and/CC
a/DT
violin/NN
plot/NN
were/VBD
visualized/VBN
using/VBG
R./NNP
p-values/NNS
were/VBD
calculated/VBN
by/IN
permutation/NN
test/NN
with/IN
1,000/CD
permutations/NNS
./.
====================
Pipeline/NN
to/TO
remove/VB
heterogeneity/NN
====================
To/TO
remove/VB
transcriptome/VBP
heterogeneity/NN
,/,
DeMix/NNP
[/(
15/CD
]/)
,/,
a/DT
statistical/JJ
tool/NN
for/IN
deconvolving/VBG
mixed/JJ
transcriptomes/VBZ
,/,
was/VBD
used/VBN
for/IN
2,803/CD
variable/JJ
genes/NNS
with/IN
a/DT
coefficient/JJ
of/IN
variation/NN
of/IN
over/IN
0.5/CD
due/JJ
to/TO
the/DT
high/JJ
requirement/NN
of/IN
computer/NN
memory/NN
./.
====================
In/IN
order/NN
to/TO
identify/VB
DEGs/NNS
confidently/RB
,/,
three/CD
different/JJ
tests/NNS
(/(
t-test/JJS
,/,
Wilcoxon/JJ
test/NN
,/,
and/CC
median/JJ
difference/NN
test/NN
)/)
were/VBD
performed/VBN
with/IN
1,000/CD
permutations/NNS
./.
====================
Using/VBG
POINTILLIST/NN
[/(
16/CD
]/)
,/,
the/DT
three/CD
p-values/NNS
from/IN
each/DT
test/NN
were/VBD
integrated/VBN
into/IN
one/CD
./.
====================
Genes/NNS
with/IN
absolute/JJ
fold-change/NN
over/IN
1.25/CD
and/CC
p-values/NNS
less/RBR
than/IN
0.01/CD
in/IN
COPD/NN
and/CC
normal/JJ
subjects/NNS
were/VBD
regarded/VBN
as/IN
DEGs/NNS
./.
====================
Functional/JJ
and/CC
pathway/NN
enrichment/JJ
assays/NNS
of/IN
DEGs/NNS
were/VBD
carried/VBN
out/RP
by/IN
DAVID/NN
[/(
17/CD
]/)
./.
====================
Biological/JJ
terms/NNS
with/IN
p-values/NNS
less/RBR
than/IN
0.01/CD
were/VBD
considered/VBN
significant/JJ
./.
====================
COPD-related/JJ
subnetworks/NNS
====================
PhenomeExpress/NN
[/(
18/CD
]/)
was/VBD
used/VBN
to/TO
build/JJ
vital/JJ
subnetworks/NNS
in/IN
COPD/NN
./.
====================
Phenotypes/NNS
relevant/JJ
to/TO
COPD/NN
were/VBD
used/VBN
as/IN
seeds/VBZ
to/TO
construct/VB
the/DT
subnetworks/NNS
./.
====================
The/DT
seed/JJ
phenotypes/NNS
were/VBD
HP:0002875/CD
(/(
exertional/JJ
dyspnea/NN
)/)
,/,
HP:0006510/NN
(/(
chronic/JJ
obstructive/JJ
pulmonary/JJ
disease/NN
)/)
,/,
MP:0001183/NN
(/(
overexpanded/VBN
pulmonary/JJ
alveoli/FW
)/)
,/,
MP:0001951/NN
(/(
abnormal/JJ
breathing/JJ
pattern/NN
)/)
,/,
MP:0010959/NN
(/(
abnormal/JJ
oxidative/JJ
phosphorylation/NN
)/)
,/,
MP:0010956/NN
(/(
abnormal/JJ
mitochondrial/JJ
ATP/NN
synthesis-coupled/JJ
electron/NN
transport/VBP
)/)
,/,
and/CC
MP:0002499/NN
(/(
chronic/JJ
inflammation/NN
)/)
./.
====================
Information/NN
on/IN
protein/NN
interactions/NNS
was/VBD
extracted/VBN
from/IN
ConsensusPathDB/NN
[/(
19/CD
]/)
./.
====================
Functional/JJ
enrichment/JJ
of/IN
subnetworks/NNS
was/VBD
examined/VBN
by/IN
the/DT
Biological/JJ
Networks/NNS
Gene/NN
Ontology/NN
tool/NN
7/CD
(/(
BiNGO/NNP
)/)
,/,
an/DT
open-source/NN
Cytoscape/NN
(/(
v2.8.1/NN
)/)
plugin/NN
to/TO
assess/VB
over-representation/NN
of/IN
gene/NN
ontology/NN
terms/NNS
in/IN
networks/NNS
[/(
20/CD
]/)
./.
====================
Subnetworks/NNS
enriched/JJ
with/IN
specific/JJ
functions/NNS
were/VBD
selected/VBN
for/IN
further/JJ
consideration/NN
./.
====================
Pipeline/NN
to/TO
predict/VB
protein/NN
subcellular/JJ
localization/NN
====================
Protein/NN
subcellular/JJ
localization/NN
was/VBD
examined/VBN
and/CC
predicted/VBN
using/VBG
the/DT
analysis/NN
scheme/VBP
suggested/VBD
by/IN
Liu/JJ
and/CC
Hu/NNP
[/(
21/CD
]/)
and/CC
support/VBP
vector/NN
machine/NN
(/(
SVM/NN
)/)
./.
====================
Information/NN
on/IN
protein/NN
interactions/NNS
and/CC
subcellular/JJ
localization/NN
was/VBD
obtained/VBN
from/IN
ConsensusPathDB/NN
[/(
19/CD
]/)
and/CC
the/DT
Human/JJ
Protein/NN
Atlas/NNS
[/(
22/CD
]/)
,/,
respectively/RB
./.
====================
Gene/NN
expression/NN
profiles/NNS
were/VBD
converted/VBN
into/IN
a/DT
matrix/NN
of/IN
maximal/JJ
information/NN
coefficients/NNS
(/(
MICs/NNS
)/)
,/,
and/CC
the/DT
relationships/NNS
between/IN
proteins/NNS
were/VBD
calculated/VBN
using/VBG
maximal/JJ
information-based/VBN
nonparametric/JJ
exploration/NN
statistics/NNS
[/(
23/CD
]/)
./.
====================
Training/VBG
and/CC
prediction/NN
with/IN
SVM/NN
were/VBD
carried/VBN
out/RP
with/IN
the/DT
e1071/NN
library/NN
in/IN
R./NNP
The/DT
MICs/NNS
for/IN
a/DT
protein/NN
pair/NN
were/VBD
computed/VBN
in/IN
individual/JJ
COPD/NN
and/CC
normal/JJ
samples/NNS
,/,
and/CC
the/DT
protein/NN
pairs/NNS
with/IN
an/DT
absolute/JJ
difference/NN
(/(
delta/NN
MIC/NN
>/JJR
0.4/CD
)/)
of/IN
2/CD
MICs/NNS
were/VBD
randomly/RB
defined/VBN
as/IN
differentially/RB
co-expressed/VBN
gene/NN
pairs/NNS
(/(
DCGPs/NNS
)/)
./.
====================
Evaluation/NN
of/IN
heterogeneity/NN
in/IN
COPD/NN
data/NNS
====================
In/IN
a/DT
previous/JJ
study/NN
by/IN
Kim/NN
et/FW
al/JJ
./.
====================
[/(
10/CD
]/)
,/,
1,420/CD
DEGs/NNS
between/IN
COPD/NN
and/CC
normal/JJ
subjects/NNS
were/VBD
identified/VBN
by/IN
student/JJ
’/CD
s/NNS
t-test/JJS
and/CC
edgeR/NN
in/IN
Biocoductor/NN
[/(
24/CD
]/)
./.
====================
To/TO
see/VB
the/DT
Euclidean/JJ
distance/NN
and/CC
relatedness/NN
between/IN
COPD/NN
and/CC
normal/JJ
subjects/NNS
,/,
PCA/NN
was/VBD
performed/VBN
(/(
Fig/NN
./.
====================
1A/NN
)/)
./.
====================
In/IN
a/DT
three-dimensional/JJ
data/NNS
space/VBP
,/,
it/PRP
was/VBD
hard/RB
to/TO
distinguish/VB
COPD/NN
samples/NNS
from/IN
normal/JJ
samples/NNS
./.
====================
Moreover/RB
,/,
three/CD
principal/JJ
components/NNS
explained/VBN
less/RBR
than/IN
one-half/DT
of/IN
the/DT
variability/NN
between/IN
samples/NNS
(/(
PC1/NN
,/,
0.422/CD
;/:
PC2/NN
,/,
0.069/CD
;/:
and/CC
PC3/NN
,/,
0.047/CD
)/)
./.
====================
These/DT
results/NNS
revealed/VBD
8/CD
heterogeneity/NN
in/IN
the/DT
COPD/NN
samples/NNS
and/CC
indicated/VBD
that/IN
simple/JJ
conventional/JJ
DEG/NN
comparison/NN
was/VBD
not/RB
enough/IN
to/TO
classify/VB
the/DT
samples/NNS
./.
====================
To/TO
identify/VB
the/DT
status/NN
of/IN
COPD/NN
samples/NNS
,/,
the/DT
average/NN
expression/NN
levels/NNS
of/IN
known/VBN
COPD/NN
marker/NN
genes/NNS
were/VBD
examined/VBN
(/(
Fig/NN
./.
====================
1B/NN
)/)
[/(
25-31/CD
]/)
./.
====================
Genes/NNS
encoding/VBG
acute/JJ
phase/NN
proteins/NNS
,/,
such/JJ
as/IN
fibrinogen/NN
α/RB
(/(
FGA/NN
)/)
and/CC
fibrinogen/NN
γ/RB
(/(
FGG/NN
)/)
,/,
were/VBD
up-regulated/VBN
in/IN
COPD/NN
./.
====================
The/DT
expression/NN
levels/NNS
of/IN
the/DT
immune/JJ
cytokines/NNS
interleukin/NN
6/CD
(/(
IL6/NN
)/)
and/CC
CXCL8/NN
(/(
IL8/NN
)/)
were/VBD
also/RB
increased/VBD
./.
====================
Genes/NNS
of/IN
immune/JJ
receptors/NNS
associated/VBN
with/IN
smoking/NN
were/VBD
highly/RB
expressed/VBN
in/IN
COPD/NN
than/IN
in/IN
normal/JJ
samples/NNS
./.
====================
However/RB
,/,
the/DT
extent/NN
of/IN
changes/NNS
was/VBD
generally/RB
less/RBR
than/IN
2-fold/JJ
,/,
suggesting/VBG
that/IN
these/DT
COPD/NN
samples/NNS
were/VBD
in/IN
the/DT
mild/JJ
stage/NN
of/IN
COPD/NN
./.
====================
Unusually/RB
,/,
the/DT
expression/NN
levels/NNS
of/IN
tumor/NN
necrosis/NN
factor/NN
(/(
TNF/NN
;/:
TNF-α/NN
)/)
and/CC
CSF2/NN
(/(
granulocyte-macrophage/JJ
colony-stimulating/JJ
factor/NN
[/(
GM-CSF/NN
]/)
)/)
were/VBD
lower/JJR
in/IN
COPD/NN
,/,
which/WDT
was/VBD
different/JJ
from/IN
previous/JJ
observations/NNS
[/(
27,28/CD
]/)
./.
====================
By/IN
analyzing/VBG
RNA-seq/NN
data/NNS
,/,
it/PRP
was/VBD
possible/JJ
to/TO
measure/VB
recombination/NN
events/NNS
in/IN
BCR/NN
and/CC
TCR/NN
loci/NNS
./.
====================
VJ/RB
recombination/NN
occurs/VBZ
in/IN
the/DT
primary/JJ
lymphoid/JJ
organs/NNS
and/CC
involves/VBZ
the/DT
joining/VBG
of/IN
the/DT
variable/JJ
(/(
V/JJ
)/)
and/CC
joining/VBG
(/(
J/NNP
)/)
chains/NNS
,/,
resulting/VBG
in/IN
the/DT
variation/NN
of/IN
amino/NN
acid/NN
sequences/NNS
in/IN
the/DT
antigen-binding/JJ
regions/NNS
of/IN
BCRs/NNS
and/CC
TCRs/NNS
./.
====================
By/IN
using/VBG
IgBlast/JJ
[/(
14/CD
]/)
,/,
frequent/JJ
VJ/NN
recombination/NN
events/NNS
in/IN
the/DT
immunoglobulin/NN
K/NN
(/(
IGK/NN
)/)
locus/NN
were/VBD
identified/VBN
./.
====================
Alpha/NN
diversity/NN
represents/VBZ
how/WRB
many/JJ
components/NNS
constitute/VBP
a/DT
particular/JJ
complex/NN
within/IN
a/DT
sample/JJ
./.
====================
In/IN
contrast/NN
,/,
beta/NN
diversity/NN
is/VBZ
the/DT
compositional/JJ
dissimilarity/NN
between/IN
samples/NNS
./.
====================
The/DT
alpha/NN
diversity/NN
levels/NNS
of/IN
the/DT
IGK/NN
locus/NN
indicated/VBD
that/IN
COPD/NN
samples/NNS
contained/VBD
marginally/RB
higher/JJR
combinatorial/JJ
diversity/NN
than/IN
normal/JJ
samples/NNS
(/(
Fig/NN
./.
====================
1C/NN
)/)
./.
====================
Besides/RB
,/,
beta/NN
diversity/NN
levels/NNS
showed/VBD
lower/JJR
similarity/NN
between/IN
COPD/NN
samples/NNS
compared/VBN
with/IN
normal/JJ
samples/NNS
(/(
Fig/NN
./.
====================
1D/CD
)/)
./.
====================
Normal/JJ
samples/NNS
were/VBD
more/RBR
similar/JJ
to/TO
each/DT
other/JJ
than/IN
to/TO
COPD/NN
samples/NNS
./.
====================
Other/JJ
immunoglobulins/NNS
(/(
IGH/NN
and/CC
IGL/NN
)/)
and/CC
TCRs/NNS
(/(
TCRA/NN
and/CC
TCRB/NN
)/)
showed/VBD
similar/JJ
patterns/NNS
in/IN
alpha/NN
and/CC
beta/NN
diversity/NN
levels/NNS
as/IN
IGK/NN
(/(
Supplementary/JJ
Fig/NN
./.
====================
1/CD
and/CC
2/CD
)/)
./.
====================
From/IN
these/DT
analyses/NNS
,/,
the/DT
COPD/NN
samples/NNS
could/MD
be/VB
regarded/VBN
9/CD
as/IN
heterogeneous/JJ
in/IN
the/DT
mild/JJ
stage/NN
of/IN
COPD/NN
./.
====================
Reduction/NN
of/IN
heterogeneity/NN
of/IN
COPD/NN
samples/NNS
====================
A/DT
workflow/NN
,/,
including/VBG
the/DT
prediction/NN
of/IN
estimates/NNS
and/CC
the/DT
deconvolution/NN
process/NN
,/,
was/VBD
set/NN
up/IN
to/TO
resolve/VB
the/DT
issue/NN
of/IN
complexity/NN
(/(
Fig/NN
./.
====================
2A/NN
)/)
./.
====================
The/DT
critical/JJ
steps/NNS
in/IN
the/DT
pipeline/NN
were/VBD
the/DT
prediction/NN
of/IN
estimates/NNS
and/CC
deconvolution/NN
./.
====================
The/DT
deconvolution/NN
process/NN
was/VBD
originally/RB
designed/VBN
to/TO
estimate/VB
the/DT
proportions/NNS
of/IN
known/VBN
sample/NN
types/NNS
in/IN
a/DT
mixture/NN
of/IN
multiple/JJ
samples/NNS
./.
====================
By/IN
assuming/VBG
the/DT
RNA-seq/NN
data/NNS
of/IN
our/PRP$
98/CD
COPD/NN
and/CC
91/CD
normal/JJ
samples/NNS
to/TO
be/VB
a/DT
mixture/NN
,/,
the/DT
deconvolution/NN
process/NN
was/VBD
applied/VBN
to/TO
extract/NN
the/DT
unique/JJ
profile/NN
of/IN
COPD/NN
samples/NNS
./.
====================
Having/VBG
many/JJ
samples/NNS
was/VBD
helpful/JJ
to/TO
increase/VB
the/DT
accuracy/NN
./.
====================
Then/RB
,/,
integrative/JJ
statistical/JJ
test/NN
was/VBD
performed/VBN
to/TO
identify/VB
confident/JJ
DEGs/NNS
./.
====================
p-values/NNS
from/IN
the/DT
three/CD
tests/NNS
were/VBD
combined/VBN
by/IN
POINTILLIST/NN
[/(
16/CD
]/)
./.
====================
In/IN
order/NN
to/TO
confirm/VB
the/DT
effect/NN
of/IN
the/DT
deconvolution/NN
,/,
expression/NN
levels/NNS
of/IN
known/VBN
marker/NN
genes/NNS
were/VBD
re-evaluated/VBN
(/(
Fig/NN
./.
====================
2B/NN
)/)
./.
====================
The/DT
p-values/NNS
of/IN
gene/NN
expression/NN
differences/NNS
in/IN
the/DT
FGA/NN
,/,
FGG/NN
,/,
IL6/NN
,/,
and/CC
CXCL8/NN
genes/NNS
were/VBD
not/RB
changed/VBN
./.
====================
Immune/JJ
receptors/NNS
associated/VBN
with/IN
smoking/NN
kept/IN
their/PRP$
higher/JJR
expression/NN
levels/NNS
in/IN
COPD/NN
versus/CC
normal/JJ
tissue/NN
./.
====================
However/RB
,/,
in/IN
contrast/NN
to/TO
Fig/NN
./.
====================
1B/NN
,/,
C-reactive/JJ
protein/NN
(/(
CRP/NN
)/)
and/CC
β-fibrinogen/NN
(/(
FGB/NN
)/)
were/VBD
now/RB
up-regulated/VBN
in/IN
COPD/NN
./.
====================
SFTPD/NN
was/VBD
significantly/RB
down-regulated/VBN
in/IN
COPD/NN
./.
====================
The/DT
expression/NN
levels/NNS
of/IN
TNF/NN
and/CC
CSF2/NN
were/VBD
not/RB
significantly/RB
different/JJ
between/IN
COPD/NN
and/CC
normal/JJ
tissue/NN
./.
====================
These/DT
results/NNS
suggest/VBP
that/IN
the/DT
gene/NN
expression/NN
profiles/NNS
of/IN
heterogeneous/JJ
samples/NNS
can/MD
be/VB
normalized/VBN
in/IN
good/JJ
agreement/NN
with/IN
known/VBN
patterns/NNS
through/IN
the/DT
deconvolution/NN
process/NN
./.
====================
DEGs/NNS
and/CC
biologically/RB
relevant/JJ
subnetworks/NNS
====================
DEGs—80/CD
up-regulated/VBD
genes/NNS
and/CC
757/CD
down-regulated/VBN
genes/NNS
in/IN
COPD—could/JJ
be/VB
10/CD
identified/VBN
by/IN
applying/VBG
the/DT
following/VBG
conditions/NNS
:/:
genes/NNS
with/IN
absolute/JJ
fold-change/NN
over/IN
1.25/CD
and/CC
p-values/NNS
less/RBR
than/IN
0.01/CD
(/(
Fig/NN
./.
====================
3A/NN
,/,
Supplementary/JJ
Table/JJ
1/CD
)/)
./.
====================
Of/IN
them/PRP
,/,
66/CD
(/(
82.5/CD
%/NN
)/)
up-regulated/VBD
genes/NNS
and/CC
501/CD
(/(
66.2/CD
%/NN
)/)
down-regulated/VBN
genes/NNS
overlapped/VBN
with/IN
the/DT
1,420/CD
genes/NNS
previously/RB
identified/VBN
by/IN
Kim/NN
et/FW
al/JJ
./.
====================
[/(
10/CD
]/)
./.
====================
However/RB
,/,
PCA/NN
of/IN
the/DT
DEGs/NNS
showed/VBD
a/DT
clear/JJ
difference/NN
between/IN
COPD/NN
samples/NNS
and/CC
normal/JJ
samples/NNS
(/(
Fig/NN
./.
====================
3B/NN
)/)
./.
====================
These/DT
DEGs/NNS
might/MD
explain/VB
the/DT
variability/NN
between/IN
samples/NNS
better/RBR
than/IN
the/DT
previously/RB
identified/VBN
DEGs/NNS
(/(
PC1/NN
,/,
0.702/CD
;/:
PC2/NN
,/,
0.031/CD
;/:
and/CC
PC3/NN
,/,
0.018/CD
)/)
./.
====================
Accordingly/RB
,/,
the/DT
performance/NN
of/IN
the/DT
prediction/NN
model/NN
with/IN
DEGs/NNS
(/(
AUC/NN
)/)
increased/VBD
from/IN
0.793/CD
to/TO
0.931/CD
./.
====================
To/TO
detect/VB
biological/JJ
functions/NNS
or/CC
pathways/NNS
closely/RB
related/JJ
to/TO
specific/JJ
genes/NNS
,/,
we/PRP
performed/VBD
enrichment/JJ
assays/NNS
with/IN
DEGs/NNS
(/(
Fig/NN
./.
====================
3C/NN
and/CC
3D/NN
)/)
./.
====================
A/DT
relatively/RB
small/JJ
number/NN
of/IN
up-regulated/VBN
genes/NNS
in/IN
COPD/NN
were/VBD
related/JJ
to/TO
several/JJ
functions/NNS
,/,
such/JJ
as/IN
smooth/JJ
muscle/NN
cell/NN
proliferation/NN
,/,
protein/NN
autophosphorylation/NN
,/,
and/CC
wound/NN
healing/NN
,/,
as/IN
previously/RB
shown/VBN
./.
====================
On/IN
the/DT
other/JJ
hand/NN
,/,
down-regulated/VBN
genes/NNS
were/VBD
associated/VBN
with/IN
translational/JJ
elongation/NN
,/,
antigen/NN
processing/NN
and/CC
presentation/NN
,/,
and/CC
oxidative/JJ
phosphorylation/NN
coupled/VBN
with/IN
electron/NN
transport/VBP
in/IN
mitochondria/NN
./.
====================
Additionally/RB
,/,
in/IN
terms/NNS
of/IN
biological/JJ
pathways/NNS
,/,
down-regulated/VBN
genes/NNS
were/VBD
linked/VBN
to/TO
the/DT
ribosome/NN
,/,
oxidative/JJ
phosphorylation/NN
,/,
the/DT
proteasome/NN
,/,
and/CC
a/DT
couple/JJ
of/IN
neurodegenerative/JJ
disorders/NNS
./.
====================
The/DT
identification/NN
of/IN
protein/NN
interaction/NN
subnetworks/NNS
using/VBG
the/DT
transcriptome/JJ
can/MD
provide/VB
useful/JJ
information/NN
on/IN
interaction/NN
modules/NNS
for/IN
specific/JJ
functions/NNS
./.
====================
Reliable/JJ
subnetworks/NNS
were/VBD
constructed/VBN
by/IN
PhenomeExpress/NN
in/IN
combination/NN
with/IN
gene/NN
expression/NN
profiles/NNS
and/CC
disease-related/JJ
phenotypes/NNS
[/(
18/CD
]/)
./.
====================
There/EX
were/VBD
five/CD
meaningful/JJ
subnetworks/NNS
significantly/RB
enriched/JJ
with/IN
specific/JJ
functions/NNS
(/(
Fig/NN
./.
====================
4A-4D/CD
)/)
./.
====================
The/DT
largest/JJS
subnetwork/NN
was/VBD
too/RB
complex/NN
to/TO
interpret/VB
(/(
Supplementary/NN
Fig/NN
./.
====================
3/CD
)/)
,/,
and/CC
it/PRP
was/VBD
further/RBR
divided/VBN
into/IN
three/CD
subnetworks/NNS
(/(
Fig/NN
./.
====================
4E-4G/NN
)/)
./.
====================
Functions/NNS
,/,
such/JJ
as/IN
electron/NN
transport/VBP
chain/NN
and/CC
translation/NN
elongation/NN
,/,
were/VBD
detected/VBN
in/IN
11/CD
subnetworks/NNS
,/,
as/IN
with/IN
DEGs/NNS
./.
====================
In/IN
contrast/NN
,/,
functions/VBZ
related/JJ
to/TO
the/DT
regulation/NN
of/IN
transcription/NN
,/,
vesicle-mediated/JJ
transport/VBP
,/,
regulation/NN
of/IN
apoptosis/NN
,/,
and/CC
immune/JJ
system/NN
processes/NNS
,/,
were/VBD
only/RB
observed/VBN
in/IN
subnetworks/NNS
./.
====================
Whereas/IN
the/DT
term/NN
‘/NN
general/JJ
antigen/NN
presenting/VBG
and/CC
presentation/NN
’/CD
was/VBD
enriched/VBN
in/IN
DEGs/NNS
,/,
their/PRP$
function/NN
was/VBD
confined/VBN
to/TO
MHC/NN
class/NN
II/CD
in/IN
a/DT
subnetwork/NN
./.
====================
DCGPs/NNS
and/CC
protein/NN
sublocalization/NN
changes/NNS
====================
One/CD
emergent/JJ
subnetwork/NN
associated/VBN
with/IN
vesicle-mediated/JJ
transport/VBP
might/MD
be/VB
linked/VBN
to/TO
the/DT
possibility/NN
that/IN
changes/NNS
in/IN
protein/NN
subcellular/JJ
localization/NN
play/VBP
an/DT
important/JJ
role/NN
in/IN
COPD/NN
development/NN
./.
====================
Protein/NN
localization/NN
was/VBD
predicted/VBN
,/,
based/VBN
on/IN
gene/NN
expression/NN
profiles/NNS
(/(
Fig/NN
./.
====================
5A/CD
)/)
./.
====================
To/TO
construct/VB
a/DT
co-expression/NN
network/NN
,/,
gene/NN
expression/NN
profiles/NNS
were/VBD
converted/VBN
into/IN
another/DT
format/IN
,/,
and/CC
co-expression/NN
relationships/NNS
of/IN
gene/NN
pairs/NNS
were/VBD
measured/VBN
using/VBG
MICs/NNS
[/(
23/CD
]/)
./.
====================
Two/CD
genes/NNS
were/VBD
regarded/VBN
as/IN
DCGPs/NNS
if/IN
the/DT
absolute/JJ
MIC/NN
changes/NNS
between/IN
COPD/NN
and/CC
normal/JJ
subjects/NNS
was/VBD
greater/JJR
than/IN
0.4/CD
./.
====================
Under/IN
this/DT
condition/NN
,/,
139/CD
up-regulated/VBD
pairs/NNS
and/CC
303/CD
down-regulated/VBN
pairs/NNS
in/IN
COPD/NN
could/MD
be/VB
identified/VBN
(/(
Fig/NN
./.
====================
5B/NN
,/,
Supplementary/JJ
Table/JJ
2/CD
)/)
./.
====================
In/IN
PCA/NN
with/IN
the/DT
DCGPs/NNS
,/,
there/EX
was/VBD
a/DT
clear/JJ
difference/NN
between/IN
COPD/NN
samples/NNS
and/CC
normal/JJ
samples/NNS
(/(
Fig/NN
./.
====================
5C/NN
)/)
,/,
even/RB
though/IN
they/PRP
showed/VBD
variability/NN
between/IN
samples/NNS
that/DT
was/VBD
not/RB
large/JJ
as/IN
with/IN
the/DT
DEGs/NNS
(/(
PC1/NN
,/,
0.102/CD
;/:
PC2/NN
,/,
0.008/CD
;/:
and/CC
PC3/NN
,/,
0.005/CD
)/)
./.
====================
The/DT
prediction/NN
model/NN
with/IN
the/DT
DCGPs/NNS
exhibited/VBD
good/JJ
performance/NN
(/(
AUC/NN
,/,
0.946/CD
)/)
./.
====================
Sixty-two/CD
genes/NNS
among/IN
424/CD
genes/NNS
in/IN
442/CD
DCGPs/NNS
overlapped/VBD
significantly/RB
with/IN
DEGs/NNS
(/(
hypergeometric/JJ
test/NN
,/,
p=/JJ
3.146e-16/CD
)/)
,/,
but/CC
the/DT
remaining/VBG
362/CD
genes/NNS
were/VBD
not/RB
matched/VBN
to/TO
DEGs/NNS
(/(
Fig/NN
./.
====================
5D/CD
)/)
./.
====================
These/DT
results/NNS
imply/VBP
that/IN
DCGPs/NNS
could/MD
be/VB
complementary/JJ
to/TO
DEGs/NNS
for/IN
understanding/VBG
gene/NN
expression/NN
profiles/NNS
./.
====================
The/DT
prediction/NN
of/IN
protein/NN
subcellular/JJ
localization/NN
is/VBZ
exemplified/VBN
in/IN
Fig/NN
./.
====================
6A/CD
./.
====================
A/DT
mitochondrial/JJ
protein/NN
,/,
NDUFA12/NN
,/,
was/VBD
selected/VBN
,/,
because/IN
it/PRP
had/VBD
8/CD
interacting/VBG
proteins/NNS
and/CC
showed/VBD
coherent/JJ
changes/NNS
in/IN
all/DT
interactions/NNS
./.
====================
The/DT
predicted/VBN
chance/NN
of/IN
NDUFA12/NN
translocating/VBG
toward/IN
12/CD
mitochondria/NN
was/VBD
increased/VBN
in/IN
COPD/NN
(/(
43.8/CD
%/NN
)/)
,/,
compared/VBN
with/IN
normal/JJ
tissue/NN
(/(
25.5/CD
%/NN
)/)
./.
====================
In/IN
COPD/NN
,/,
protein/NN
interactions/NNS
between/IN
NDUFA12/NN
and/CC
other/JJ
mitochondrial/JJ
proteins/NNS
were/VBD
reinforced/VBN
./.
====================
However/RB
,/,
the/DT
actual/JJ
protein/NN
sublocalization/NN
changes/NNS
were/VBD
expected/VBN
to/TO
be/VB
much/RB
more/RBR
complex/NN
when/WRB
considering/VBG
all/DT
protein/NN
interactions/NNS
./.
====================
Our/PRP$
analysis/NN
workflow/VBP
was/VBD
designed/VBN
to/TO
include/VB
all/DT
protein/NN
interactions/NNS
and/CC
thus/RB
predicted/VBN
the/DT
probabilities/NNS
of/IN
10/CD
subcellular/JJ
locations/NNS
of/IN
each/DT
protein/NN
for/IN
each/DT
status/NN
(/(
Fig/NN
./.
====================
5A/CD
)/)
./.
====================
Out/CC
of/IN
76/CD
significant/JJ
subcellular/JJ
localization/NN
changes/NNS
between/IN
COPD/NN
and/CC
normal/JJ
tissue/NN
,/,
19/CD
(/(
25.0/CD
%/NN
)/)
were/VBD
related/JJ
to/TO
mitochondria/NN
and/CC
52/CD
(/(
68.4/CD
%/NN
)/)
were/VBD
related/JJ
to/TO
the/DT
nucleus/NN
(/(
Fig/NN
./.
====================
6B/CD
)/)
./.
====================
The/DT
predicted/VBN
probabilities/NNS
of/IN
subcellular/JJ
locations/NNS
of/IN
the/DT
mitochondria-related/JJ
proteins/NNS
were/VBD
examined/VBN
(/(
Fig/NN
./.
====================
6C/NN
)/)
./.
====================
Except/IN
for/IN
ILF3/NN
,/,
all/DT
proteins/NNS
showed/VBD
higher/JJR
chances/NNS
of/IN
localizing/VBG
to/TO
mitochondria/NN
in/IN
COPD/NN
than/IN
in/IN
normal/JJ
tissue/NN
./.
====================
Seven/CD
of/IN
them/PRP
were/VBD
mitochondrial/JJ
ribosomal/JJ
proteins/NNS
,/,
and/CC
other/JJ
proteins/NNS
,/,
such/JJ
as/IN
CYC1/NN
,/,
ATP5C1/NN
,/,
NDUFA12/NN
,/,
C1QBP/NN
,/,
ATP5A1/NN
,/,
SDHB/NN
,/,
ATP5O/NN
,/,
ECH1/NN
,/,
ACADVL/NN
,/,
and/CC
SFXN3/NN
,/,
acted/VBD
on/IN
the/DT
matrix/NN
of/IN
mitochondria/NN
./.
====================
Collectively/RB
,/,
proteins/NNS
targeting/VBG
mitochondria/NN
might/MD
be/VB
influenced/VBN
by/IN
mitochondrial/JJ
dysfunction/NN
in/IN
COPD/NN
./.
====================
COPD/NN
is/VBZ
a/DT
complex/NN
and/CC
heterogeneous/JJ
disease/NN
,/,
and/CC
thus/RB
,/,
it/PRP
is/VBZ
not/RB
easy/RB
to/TO
investigate/VB
the/DT
pathogenesis/NN
and/CC
diagnosis/NN
of/IN
COPD/NN
[/(
3/CD
]/)
./.
====================
Previously/RB
,/,
Kim/NN
et/FW
al/JJ
./.
====================
[/(
10/CD
]/)
performed/VBN
RNA-seq/NN
analysis/NN
with/IN
98/CD
COPD/NN
samples/NNS
and/CC
91/CD
normal/JJ
samples/NNS
./.
====================
However/RB
,/,
DEGs/NNS
identified/VBN
by/IN
a/DT
simple/JJ
calculation/NN
of/IN
fold-change/NN
in/IN
gene/NN
expression/NN
level/NN
might/MD
not/RB
be/VB
useful—especially/RB
in/IN
this/DT
study/NN
:/:
COPD/NN
versus/CC
normal/JJ
(/(
Fig/NN
./.
====================
1A/NN
)/)
./.
====================
The/DT
heterogeneity/NN
might/MD
be/VB
attributed/VBN
to/TO
a/DT
number/NN
of/IN
different/JJ
pathological/JJ
processes/NNS
./.
====================
Among/IN
them/PRP
,/,
bacteria/NNS
have/VBP
been/VBN
reported/VBN
as/IN
one/CD
of/IN
the/DT
major/JJ
causes/VBZ
in/IN
the/DT
exacerbation/NN
of/IN
COPD/NN
,/,
contributing/VBG
to/TO
the/DT
severe/JJ
inflammatory/JJ
response/NN
in/IN
the/DT
13/CD
airways/NNS
[/(
32/CD
]/)
./.
====================
While/IN
mild-to-moderate/NN
COPD/NN
exhibits/VBZ
higher/JJR
diversity/NN
in/IN
the/DT
bacterial/JJ
population/NN
[/(
33/CD
]/)
,/,
severe/JJ
COPD/NN
shows/VBZ
lower/JJR
diversity/NN
[/(
34/CD
]/)
./.
====================
We/PRP
confirmed/VBD
that/IN
our/PRP$
COPD/NN
data/NNS
were/VBD
in/IN
the/DT
mild/JJ
stage/NN
,/,
based/VBN
on/IN
the/DT
expression/NN
levels/NNS
of/IN
known/VBN
marker/NN
genes/NNS
(/(
Fig/NN
./.
====================
1B/NN
)/)
./.
====================
These/DT
COPD/NN
samples/NNS
exhibited/VBD
a/DT
marginal/JJ
but/CC
consistent/JJ
rise/NN
in/IN
combinatorial/JJ
diversity/NN
in/IN
all/DT
BCR/NN
and/CC
TCR/NN
loci/NNS
(/(
Fig/NN
./.
====================
1C/NN
,/,
Supplementary/JJ
Fig/NN
./.
====================
1/CD
)/)
./.
====================
It/PRP
is/VBZ
possible/JJ
that/IN
increased/VBD
diversity/NN
of/IN
the/DT
microbiome/NN
in/IN
the/DT
mild/JJ
stage/NN
of/IN
COPD/NN
led/VBD
to/TO
increased/VBN
diversity/NN
of/IN
BCR/NN
and/CC
TCR/NN
loci/NNS
./.
====================
Accordingly/RB
,/,
a/DT
lower/JJR
level/NN
of/IN
similarity/NN
was/VBD
observed/VBN
between/IN
COPD/NN
samples/NNS
compared/VBN
with/IN
normal/JJ
samples/NNS
(/(
Fig/NN
./.
====================
1D/CD
,/,
Supplementary/JJ
Fig/NN
./.
====================
2/CD
)/)
./.
====================
Our/PRP$
analysis/NN
pipeline/NN
to/TO
identify/VB
DEGs/NNS
was/VBD
performed/VBN
considering/VBG
two/CD
aspects/NNS
:/:
heterogeneity/NN
and/CC
confidence/NN
(/(
Fig/NN
./.
====================
2A/NN
)/)
./.
====================
First/RB
,/,
computational/JJ
deconvolution/NN
reduced/VBD
the/DT
heterogeneity/NN
between/IN
COPD/NN
samples/NNS
./.
====================
Second/JJ
,/,
integrative/JJ
statistical/JJ
tests/NNS
were/VBD
applied/VBN
to/TO
identify/VB
confident/JJ
DEGs/NNS
./.
====================
It/PRP
is/VBZ
known/VBN
that/IN
a/DT
combination/NN
of/IN
t-test/JJS
,/,
Wilcoxon/JJ
test/NN
,/,
and/CC
median/JJ
difference/NN
test/NN
can/MD
reduce/VB
the/DT
overestimation/NN
by/IN
removing/VBG
biases/VBZ
[/(
35/CD
]/)
,/,
because/IN
conventional/JJ
t-test-based/VBN
tools/NNS
tend/CC
to/TO
calculate/JJ
p-values/NNS
too/RB
optimistically/RB
when/WRB
they/PRP
are/VBP
applied/VBN
to/TO
a/DT
large/JJ
number/NN
of/IN
samples/NNS
[/(
10/CD
]/)
./.
====================
By/IN
reducing/VBG
the/DT
heterogeneity/NN
,/,
gene/NN
expression/NN
profiles/NNS
of/IN
COPD/NN
samples/NNS
could/MD
become/VB
consistent/JJ
with/IN
known/VBN
expression/NN
patterns/NNS
of/IN
marker/NN
genes/NNS
./.
====================
The/DT
DEGs/NNS
that/DT
were/VBD
identified/VBN
in/IN
our/PRP$
pipeline/NN
were/VBD
better/RBR
in/IN
distinguishing/VBG
COPD/NN
from/IN
normal/JJ
subjects/NNS
than/IN
previously/RB
defined/VBN
DEGs/NNS
(/(
Fig/NN
./.
====================
3A/NN
and/CC
3B/NN
)/)
./.
====================
Through/IN
deconvolution/NN
,/,
gene/NN
expression/NN
profiles/NNS
among/IN
COPD/NN
samples/NNS
could/MD
become/VB
consistent/JJ
when/WRB
examined/VBN
,/,
based/VBN
on/IN
known/VBN
expression/NN
patterns/NNS
of/IN
marker/NN
genes/NNS
./.
====================
Acute-phase/JJ
proteins/NNS
,/,
such/JJ
as/IN
CRP/NN
,/,
acute-phase/JJ
serum/NN
amyloid/NN
A/DT
,/,
and/CC
fibrinogens/NNS
,/,
are/VBP
well/RB
known/VBN
and/CC
are/VBP
induced/VBN
in/IN
response/NN
to/TO
inflammation/NN
and/CC
in/IN
COPD/NN
[/(
26/CD
]/)
./.
====================
IL6/NN
,/,
CXCL8/NN
(/(
IL8/NN
)/)
,/,
TNF/NN
(/(
TNF/NN
α/NN
)/)
,/,
and/CC
CSF2/NN
(/(
GM-CSF/NN
)/)
are/VBP
airway/NN
inflammatory/JJ
cytokines/NNS
that/WDT
are/VBP
up-regulated/VBN
in/IN
COPD/NN
patients/NNS
[/(
27,28/CD
]/)
./.
====================
The/DT
levels/NNS
of/IN
immune/JJ
receptors/NNS
,/,
such/JJ
as/IN
TLR2/NN
,/,
14/CD
TLR4/NN
,/,
and/CC
IL1R1/NN
,/,
increase/VBP
with/IN
smoking/NN
[/(
29/CD
]/)
,/,
but/CC
the/DT
levels/NNS
of/IN
surfactant/JJ
protein/NN
D/NN
decrease/NN
[/(
30/CD
]/)
./.
====================
Regardless/RB
of/IN
deconvolution/NN
,/,
some/DT
acute-phase/JJ
proteins/NNS
(/(
FGA/NN
,/,
FGG/NN
)/)
,/,
cytokines/NNS
(/(
IL6/NN
,/,
CXCL8/NN
)/)
,/,
and/CC
immune/JJ
receptors/NNS
were/VBD
consistently/RB
up-regulated/VBN
in/IN
COPD/NN
./.
====================
However/RB
,/,
CRP/NN
and/CC
FGB/NN
were/VBD
up-regulated/VBN
and/CC
SFTPD/NN
was/VBD
down-regulated/VBN
in/IN
COPD/NN
only/RB
after/IN
deconvolution/NN
./.
====================
Moreover/RB
,/,
TNF/NN
and/CC
CSF2/NN
were/VBD
no/DT
longer/RBR
significantly/RB
down-regulated/VBN
./.
====================
These/DT
observations/NNS
could/MD
be/VB
identified/VBN
,/,
because/IN
sample/NN
heterogeneity/NN
was/VBD
considered/VBN
in/IN
the/DT
analysis/NN
./.
====================
Up-regulated/JJ
genes/NNS
in/IN
COPD/NN
were/VBD
related/JJ
with/IN
to/TO
functions/NNS
,/,
such/JJ
as/IN
smooth/JJ
muscle/NN
cell/NN
proliferation/NN
,/,
protein/NN
autophosphorylation/NN
,/,
and/CC
wound/NN
healing/NN
(/(
Fig/NN
./.
====================
3C/NN
)/)
,/,
consistent/JJ
with/IN
a/DT
previous/JJ
report/NN
that/IN
oxidative/JJ
stress-induced/JJ
mitochondrial/JJ
dysfunction/NN
induces/VBZ
inflammation/NN
and/CC
airway/NN
smooth/JJ
muscle/NN
remodeling/NN
in/IN
COPD/NN
[/(
36/CD
]/)
./.
====================
On/IN
the/DT
other/JJ
hand/NN
,/,
down-regulated/VBN
genes/NNS
in/IN
COPD/NN
were/VBD
relevant/JJ
to/TO
translational/JJ
elongation/NN
,/,
oxidative/JJ
phosphorylation/NN
coupled/VBN
to/TO
electron/NN
transport/VBP
in/IN
mitochondria/NN
,/,
and/CC
,/,
in/IN
particular/JJ
,/,
neurodegenerative/JJ
disorders/NNS
(/(
Fig/NN
./.
====================
3D/NN
)/)
,/,
agreeing/VBG
that/DT
COPD/NN
patients/NNS
are/VBP
likely/JJ
to/TO
develop/VB
specific/JJ
cognitive/JJ
impairments/NNS
[/(
37/CD
]/)
./.
====================
Identification/NN
of/IN
protein/NN
interaction/NN
subnetworks/NNS
shed/VBD
light/NN
on/IN
specific/JJ
functions/NNS
of/IN
interaction/NN
modules/NNS
related/JJ
to/TO
the/DT
typical/JJ
phenotypes/NNS
of/IN
COPD/NN
(/(
Fig/NN
./.
====================
4/CD
)/)
./.
====================
Functions/NNS
related/JJ
to/TO
the/DT
regulation/NN
of/IN
transcription/NN
,/,
vesicle-mediated/JJ
transport/VBP
,/,
regulation/NN
of/IN
apoptosis/NN
,/,
and/CC
immune/JJ
system/NN
processes/NNS
were/VBD
only/RB
observed/VBN
in/IN
subnetworks/NNS
,/,
not/RB
in/IN
DEGs/NNS
./.
====================
Furthermore/RB
,/,
antigen/NN
presentation/NN
was/VBD
more/RBR
confined/VBN
to/TO
MHC/NN
class/NN
II/CD
./.
====================
In/IN
this/DT
analysis/NN
,/,
the/DT
levels/NNS
of/IN
MHC/NN
class/NN
II/CD
genes/NNS
and/CC
some/DT
immune/JJ
components/NNS
decreased/VBD
,/,
whereas/IN
other/JJ
immune/JJ
components/NNS
were/VBD
down-regulated/VBN
in/IN
COPD/NN
,/,
showing/VBG
the/DT
complexity/NN
of/IN
immune/JJ
responses/NNS
in/IN
COPD/NN
./.
====================
One/CD
attractive/JJ
subnetwork/NN
associated/VBN
with/IN
vesicle-mediated/JJ
transport/VBP
raised/VBD
the/DT
question/NN
of/IN
whether/IN
protein/NN
subcellular/JJ
localization/NN
plays/VBZ
some/DT
role/NN
in/IN
COPD/NN
./.
====================
A/DT
group/NN
of/IN
proteins/NNS
with/IN
subcellular/JJ
localization/NN
changes/NNS
in/IN
COPD/NN
were/VBD
predicted/VBN
by/IN
measuring/VBG
co-expression/NN
scores/VBZ
using/VBG
information/NN
on/IN
protein/NN
interaction/NN
and/CC
subcellular/JJ
localization/NN
(/(
Figs/NNS
./.
====================
5/CD
and/CC
6/CD
)/)
./.
====================
Interestingly/RB
,/,
one-quarter/RBR
of/IN
predicted/VBN
changes/NNS
were/VBD
related/JJ
to/TO
mitochondria/NN
,/,
suggesting/VBG
that/IN
proteins/NNS
targeting/VBG
mitochondria/NN
might/MD
be/VB
influenced/VBN
by/IN
mitochondrial/JJ
dysfunction/NN
./.
====================
Mitochondrial/JJ
ribosomal/JJ
proteins/NNS
and/CC
other/JJ
proteins/NNS
on/IN
the/DT
mitochondrial/JJ
matrix/NN
were/VBD
enriched/VBN
in/IN
mitochondria/NN
in/IN
COPD/NN
cases/NNS
./.
====================
Here/RB
,/,
we/PRP
used/VBD
public/JJ
gene/NN
expression/NN
profiles/NNS
generated/VBN
from/IN
COPD/NN
and/CC
normal/JJ
subjects/NNS
and/CC
re-evaluated/VBD
the/DT
differential/JJ
transcriptomes/NNS
by/IN
removing/VBG
sample/NN
heterogeneity/NN
./.
====================
The/DT
overall/JJ
data/NNS
analysis/NN
revealed/VBD
a/DT
group/NN
of/IN
gene/NN
expression/NN
changes/NNS
that/WDT
were/VBD
missed/VBN
in/IN
previous/JJ
research/NN
./.
====================
Co-expression/NN
relationships/NNS
between/IN
conditions/NNS
could/MD
be/VB
inferred/VBN
from/IN
gene/NN
expression/NN
profiles/NNS
and/CC
might/MD
be/VB
useful/JJ
in/IN
classifying/VBG
samples/NNS
and/CC
predicting/VBG
protein/NN
subcellular/JJ
localization/NN
./.
====================
In/IN
conclusion/NN
,/,
COPD/NN
is/VBZ
a/DT
complex/NN
and/CC
heterogeneous/JJ
disease/NN
./.
====================
The/DT
newly/RB
identified/VBN
DEGs/NNS
in/IN
this/DT
study/NN
and/CC
DCGPs/NNS
could/MD
partially/RB
explain/VBP
COPD/NN
pathogenesis/NN
in/IN
the/DT
mild/JJ
stage/NN
./.
====================
We/PRP
expect/VBP
that/DT
our/PRP$
strategy/NN
of/IN
analyzing/VBG
heterogeneous/JJ
samples/NNS
will/MD
be/VB
applicable/JJ
to/TO
other/JJ
systems/NNS
./.
====================
Heterogeneous/JJ
chronic/JJ
obstructive/JJ
pulmonary/JJ
disease/NN
(/(
COPD/NN
)/)
samples/NNS
in/IN
the/DT
mild/JJ
stage/NN
./.
====================
(/(
A/DT
)/)
Principal/JJ
component/NN
analysis/NN
plot/NN
depicting/VBG
relative/JJ
similarities/NNS
between/IN
COPD/NN
samples/NNS
(/(
red/JJ
)/)
and/CC
normal/JJ
(/(
NOR/NN
)/)
samples/NNS
(/(
blue/JJ
)/)
using/VBG
previously/RB
identified/VBN
differentially/RB
expressed/VBN
genes/NNS
./.
====================
(/(
B/NN
)/)
Expression/NN
levels/NNS
of/IN
COPD/NN
marker/NN
genes/NNS
./.
====================
Recep./NN
,/,
receptor/NN
;/:
S./NNP
,/,
surfactant/JJ
;/:
NOR/NN
./.
====================
normal/JJ
./.
====================
*p/RB
</JJR
0.01/CD
,/,
**p/JJ
</JJR
0.0001/CD
by/IN
student/JJ
’/CD
s/NNS
t-test/JJS
./.
====================
(/(
C/NN
)/)
Alpha/NN
diversity/NN
of/IN
VJ/NN
combinations/NNS
in/IN
IGK/NN
./.
====================
(/(
D/NN
)/)
Beta/NN
diversity/NN
showing/VBG
an/DT
inverse/JJ
relation/NN
with/IN
the/DT
compositional/JJ
similarity/NN
between/IN
samples/NNS
in/IN
terms/NNS
of/IN
VJ/NN
combinations/NNS
in/IN
IGK/NN
./.
====================
p-values/NNS
were/VBD
calculated/VBN
after/IN
1,000/CD
per/FW
bmutation/NN
./.
====================
Deconvolution/NN
of/IN
chronic/JJ
obstructive/JJ
pulmonary/JJ
disease/NN
(/(
COPD/NN
)/)
samples/NNS
increases/VBZ
the/DT
difference/NN
between/IN
COPD/NN
and/CC
normal/JJ
(/(
NOR/NN
)/)
tissue/NN
./.
====================
(/(
A/NN
)/)
Deconvolution/NN
process/NN
to/TO
identify/VB
differentially/RB
expressed/VBN
genes/NNS
./.
====================
(/(
B/NN
)/)
Expression/NN
levels/NNS
of/IN
COPD/NN
marker/NN
genes/NNS
after/IN
deconvolution/NN
./.
====================
Recep./NN
,/,
receptor/NN
;/:
S./NNP
,/,
surfactant/JJ
;/:
NOR/NN
./.
====================
normal/JJ
./.
====================
*p/RB
</JJR
0.01/CD
,/,
**p/JJ
</JJR
0.0001/CD
by/IN
student/JJ
’/CD
s/NNS
t-test/JJS
./.
====================
Differentially/RB
expressed/VBN
genes/NNS
(/(
DEGs/NNS
)/)
between/IN
chronic/JJ
obstructive/JJ
pulmonary/JJ
disease/NN
(/(
COPD/NN
)/)
and/CC
normal/JJ
tissue/NN
./.
====================
(/(
A/NN
)/)
Scatterplot/NN
of/IN
gene/NN
expression/NN
levels/NNS
./.
====================
Red/VBN
and/CC
blue/JJ
dots/NNS
represent/VBP
up-regulated/VBN
and/CC
down-regulated/VBN
genes/NNS
in/IN
COPD/NN
compared/VBN
with/IN
normal/JJ
tissue/NN
,/,
respectively/RB
./.
====================
(/(
B/NN
)/)
Principal/JJ
component/NN
analysis/NN
plot/NN
depicting/VBG
relative/JJ
similarities/NNS
between/IN
COPD/NN
samples/NNS
(/(
red/JJ
)/)
and/CC
normal/JJ
samples/NNS
(/(
blue/JJ
)/)
using/VBG
DEGs/NNS
./.
====================
(/(
C/NN
,/,
D/NN
)/)
Biological/JJ
functions/NNS
(/(
C/NN
)/)
and/CC
pathways/NNS
(/(
D/NN
)/)
highly/RB
enriched/VBN
in/IN
up-regulated/VBN
(/(
red/JJ
)/)
and/CC
down-regulated/VBN
(/(
blue/JJ
)/)
genes/NNS
./.
====================
Individual/JJ
bars/VBZ
demonstrate/VBP
fold-changes/NNS
relative/JJ
to/TO
background/NN
,/,
and/CC
lines/NNS
display/VBP
their/PRP$
p-values/NNS
./.
====================
Biologically/RB
relevant/JJ
subnetworks/NNS
in/IN
consideration/NN
of/IN
certain/JJ
disease/NN
phenotypes/NNS
and/CC
gene/NN
expression/NN
changes/NNS
./.
====================
(/(
A–G/NN
)/)
Letters/NNS
at/IN
the/DT
top/NN
are/VBP
the/DT
most/JJS
highly/RB
enriched/VBN
biological/JJ
functions/NNS
in/IN
individual/JJ
subnetworks/NNS
./.
====================
Differentially/RB
expressed/VBN
pairs/NNS
(/(
DEPs/NNS
)/)
between/IN
chronic/JJ
obstructive/JJ
pulmonary/JJ
disease/NN
(/(
COPD/NN
)/)
and/CC
normal/JJ
(/(
NOR/NN
)/)
samples/NNS
./.
====================
(/(
A/NN
)/)
Pipeline/NN
to/TO
predict/VB
protein/NN
sublocalization/NN
from/IN
gene/NN
expression/NN
profiles/NNS
./.
====================
(/(
B/NN
)/)
Maximal/JJ
information/NN
coefficient/JJ
(/(
MIC/NN
)/)
scores/VBZ
for/IN
describing/VBG
coexpression/NN
changes/NNS
between/IN
two/CD
genes/NNS
./.
====================
Red/VBN
and/CC
blue/JJ
dots/NNS
represent/VBP
up-regulated/VBN
and/CC
downregulated/VBD
pairs/NNS
in/IN
COPD/NN
compared/VBN
with/IN
NOR/NN
samples/NNS
,/,
respectively/RB
./.
====================
(/(
C/NN
)/)
Principal/JJ
component/NN
analysis/NN
plot/NN
depicting/VBG
relative/JJ
similarities/NNS
between/IN
COPD/NN
(/(
red/JJ
)/)
and/CC
NOR/NN
samples/NNS
(/(
blue/JJ
)/)
using/VBG
DEPs/NNS
./.
====================
(/(
D/NN
)/)
Venn/NNP
diagram/NN
showing/VBG
overlap/IN
between/IN
differentially/RB
expressed/VBN
genes/NNS
(/(
DEGs/NNS
)/)
and/CC
DEPs/NNS
./.
====================
DCGP/NN
,/,
differentially/RB
co-expressed/VBN
gene/NN
pairs/NNS
./.
====================
p-values/NNS
were/VBD
calculated/VBN
by/IN
hypergeometric/JJ
test/NN
./.
====================
Prediction/NN
of/IN
protein/NN
subcellular/JJ
localization/NN
changes/NNS
between/IN
chronic/JJ
obstructive/JJ
pulmonary/JJ
disease/NN
(/(
COPD/NN
)/)
and/CC
normal/JJ
(/(
NOR/NN
)/)
samples/NNS
./.
====================
(/(
A/NN
)/)
The/DT
correlation/NN
scores/VBZ
between/IN
NDUFA12/NN
and/CC
other/JJ
mitochondrial/JJ
proteins/NNS
in/IN
NOR/NN
and/CC
COPD/NN
samples/NNS
./.
====================
The/DT
thickness/JJ
and/CC
color/JJ
of/IN
the/DT
edges/NNS
were/VBD
determined/VBN
by/IN
maximal/JJ
information/NN
coefficient/JJ
(/(
MIC/NN
)/)
./.
====================
(/(
B/NN
)/)
Genes/NNS
with/IN
significant/JJ
subcellular/JJ
localization/NN
changes/NNS
between/IN
COPD/NN
and/CC
NOR/NN
samples/NNS
./.
====================
(/(
C/NN
)/)
Heatmap/NN
demonstrating/VBG
probability/NN
of/IN
changes/NNS
in/IN
mitochondria-related/JJ
proteins/NNS
./.
====================
